Pharvaris NV
PHVS
View Detailed Chart
28.380USD
+0.660+2.38%
Close 11/28, 13:00（ET）Quotes delayed by 15 min
1.84BMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+2.38%
5 Days
+14.30%
1 Month
+28.53%
6 Months
+69.74%
Year to Date
+48.04%
1 Year
+29.59%
View Detailed Chart
TradingKey Stock Score of Pharvaris NV
Currency: USD Updated: 2025-10-27Key Insights
Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Pharvaris NV's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
12
analysts
Buy
Current Rating
37.083
Target Price
+30.67%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Pharvaris NV Highlights
StrengthsRisks
Pharvaris BV is a Switzerland-based clinical-stage company. The activity of the Company focuses on producing oral bradykinin B2-receptor antagonists and is advancing new alternatives to injected therapies for all sub-types of hereditary angioedema (HAE).
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 0.00.
Undervalued
The company’s latest PE is -9.76, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 48.75M shares, decreasing 3.62% quarter-over-quarter.
Held by Andreas Halvorsen
Star Investor Andreas Halvorsen holds 3.65M shares of this stock.
Pharvaris NV News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Pharvaris NV Info
Pharvaris BV is a Switzerland-based clinical-stage company. The activity of the Company focuses on producing oral bradykinin B2-receptor antagonists and is advancing new alternatives to injected therapies for all sub-types of hereditary angioedema (HAE).
Ticker SymbolPHVS
CompanyPharvaris NV
CEOMr. Berndt Modig, CPA
Websitehttps://pharvaris.com/
FAQs
What is the current price of Pharvaris NV (PHVS)?
The current price of Pharvaris NV (PHVS) is 28.380.
What is the symbol of Pharvaris NV?
The ticker symbol of Pharvaris NV is PHVS.
What is the 52-week high of Pharvaris NV?
The 52-week high of Pharvaris NV is 28.480.
What is the 52-week low of Pharvaris NV?
The 52-week low of Pharvaris NV is 11.510.
What is the market capitalization of Pharvaris NV?
The market capitalization of Pharvaris NV is 1.84B.
What is the net income of Pharvaris NV?
The net income of Pharvaris NV is -100.88M.
Is Pharvaris NV (PHVS) currently rated as Buy, Hold, or Sell?
According to analysts, Pharvaris NV (PHVS) has an overall rating of Buy, with a price target of 37.083.
What is the Earnings Per Share (EPS TTM) of Pharvaris NV (PHVS)?
The Earnings Per Share (EPS TTM) of Pharvaris NV (PHVS) is -2.338.
Related Instruments
-2.68%
-0.31%
+0.07%
-0.63%
+0.21%
-0.08%
+0.26%
+1.23%
-1.29%
0.00%
-0.30%
+0.33%
-0.26%
-0.13%
-0.39%
+0.15%
-0.53%
0.00%
+1.37%
+0.41%Popular Symbols
